A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics

Trial Profile

A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Paliperidone (Primary) ; Antipsychotics
  • Indications Psychotic disorders; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms DREaM
  • Sponsors Janssen
  • Most Recent Events

    • 24 May 2017 Results presented at the 170th Annual Meeting of the American Psychiatric Association
    • 24 May 2017 Baseline demographics and clinical characteristics (n=71, as of Sep 2016, US population), presented at the 170th Annual Meeting of the American Psychiatric Association.
    • 08 May 2017 Planned End Date changed from 20 May 2019 to 19 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top